Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bionic Pancreas Feasibility Trial with Dasiglucagon
NCT02971228Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasiglucagon in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Zealand Pharma. Primary endpoint: Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters up to 50 days. Started Nov 2016; status: completed.
02
Drugs
dasiglucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02971228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971228.